Evidence / Study 01
Global cerebral ischemia: edema and AQP4.
A source-mapped mouse study summary with direction-of-effect visualization and explicit limitations.
03 / evidence
No invented percentages. The figure keeps the direction and the unknowns visible.
preclinicalBilateral common carotid artery ligation modelpreclinical_in_vivosource_mapped
Research question
Explore source-reported changes in brain water content, edema and AQP4 in a global cerebral ischemia model.
Methods
ModelBilateral common carotid artery ligation
SpeciesMouse
InterventionAildenafil phosphate at source-described dose levels
Dose10 mg/kg described as the preferred dose in the source summary
TimingNot specified in the current source summary
ComparatorNot specified in the current source summary
- Exact group sizes and numerical endpoint values are not present in the current source map.
Source results
| Endpoint | Timepoint | Source result |
|---|---|---|
| Source-described preferred dose | — | 10 mg/kg |
| Mouse-to-human conversion factor | — | 12.3 × |
| Brain water content | — | decrease described in the source summary |
| AQP4 | — | decrease described in the source summary |
FIG. 03Conceptual
Edema and AQP4 direction-of-effect
Interpretation
This is a direction-of-effect summary from a company source. It is not presented as a quantified efficacy result.
Limitations
- Numerical brain water content, AQP4 values, group sizes and statistical results are not available in the current source map.
10 mg/kgPreferred doseSource described
12.3×Conversion factorApproximate
Continue exploring
Take the question one layer deeper.
01MCAO treatment window.A timeline for the source-reported 2 h, 6 h and 24 h treatment-window narrative.02One canvas. Three connected directions.An interactive, source-aware mechanism narrative across vascular response, neurovascular recovery and neuroprotection.03Aildenafil phosphate, presented with precision.A source-mapped product profile for Aildenafil phosphate tablets, separated from the evidence library.04A precise route for scientific questions.A static first medical-information contact path for evidence and safety questions.